Tri Locum Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Tri Locum Partners's VRTX Position: Q2 2026 in Review
Tri Locum Partners increased its Vertex Pharmaceuticals (VRTX) stake by 56% in Q2 2026, buying an estimated $32.1M and bringing the position to 201,791 shares worth $100M. The position accounts for 12.33% of the portfolio, ranked #2.
Tri Locum Partners first reported a position in VRTX in Q2 2023 and has held it in 4 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Tri Locum Partners held 201,791 shares of Vertex Pharmaceuticals worth $100M as of Q2 2026.
- Tri Locum Partners bought 72,477 Vertex Pharmaceuticals shares in Q2 2026, an estimated $32.1M.
- Vertex Pharmaceuticals made up 12.33% of Tri Locum Partners's portfolio in Q2 2026, its #2 holding.
- Tri Locum Partners first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.